Systemic inflammation is associated with MCI and its subtypes: The Sydney memory and aging study

Dementia and Geriatric Cognitive Disorders

Volumn 30, Issue 6, 2011, Pages 569-578

  Trollor, Julian N ^a   Smith, Evelyn ^a   Baune, Bernhard T ^e   Kochan, Nicole A ^a,c   Campbell, Lesley ^d,e   Samaras, Katherine ^d,e   Crawford, John ^a   Brodaty, Henry ^a,b   Sachdev, Perminder ^a,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e JAMES COOK UNIVERSITY   (Australia)

Author keywords

Cytokines; Dementia; Inflammation; Inflammatory markers; Mild cognitive impairment

Indexed keywords

APOLIPOPROTEIN E; C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

AGED; ARTICLE; AUSTRALIA; COHORT ANALYSIS; CONFOUNDING VARIABLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC ASSOCIATION; HUMAN; INFLAMMATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COGNITION; COGNITION DISORDERS; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EDUCATION; FEMALE; GENOTYPE; HUMANS; INFLAMMATION; MALE; MEMORY; RISK FACTORS; SEX FACTORS;

EID: 79251486707     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322092     Document Type: Article

References (76)

1. Petersen RC: Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183-194.
2. Petersen RC, Negash S: Mild cognitive impairment: an overview. CNS Spectr 2008; 13: 45-53.
3. Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR Jr, Weiner MW, Jagust WJ, on behalf of the Alzheimer's Disease Neuroimaging Initiative: Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010; 75: 230-238.
4. Sperling R, et al.: Proposed criteria for preclinical Alzheimer's disease. 2010. http://www.alz.org/research/diagnostic-criteria/.
5. Giunta B, Fernandez F, Nikolic WV, Obregon D, Rrapo E, Town T, Tan J: Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflammation 2008; 5: 51-66.
6. Duong T, Nikolaeva M, Acton PJ: C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer's disease. Brain Res 1997; 749: 152-156.
7. Dimopoulos N, Piperi C, Salonicioti A, et al.: Indicies of low-grade chronic inflammation correlate with early cognitive deterioration in an elderly Greek population, Neurosci Lett 2006; 398: 118-123.
8. Engelhart M, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, Stijnen T, Hofman A, Witteman JCM, Breteler MMB: Inflammatory proteins in plasma and the risk of dementia. Arch Neurol 2004; 61: 668-672.
9. Alvarez A, Cacabelos R, Sanpedro C, Garcia- Fantini M, Aleixandre M: Serum TNF-levels are increased and correlate negatively with free IGF-I in Alzheimer disease. Neurobiol Aging 2007; 28: 533-536.
10. Bermejo P, Martin-Aragon S, Benedi J, et al.: Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol Lett 2008; 117: 198-202.
11. Deniz-Naranjo MC, Munoz-Fernandez C, Alemany-Rodriguez MJ, Perez-Vieitez MC, Aladro-Benito Y, Irurita-Latasa J, Sanchez- Garcia F: Cytokine IL-1 beta but not IL-1 alpha promoter polymorphism is associated with Alzheimer disease in a population from the Canary Islands, Spain. Eur J Neurol 2008; 15: 1080-1084.
12. Licastro F, Pedrini S, Caputo L, et al.: Increased plasma levels of interleukin-1, interleukin-6 and -antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J Neuroimmunology 2000; 103: 97-102.
13. Singh VK, Guthikonda P: Circulating cytokines in Alzheimer's disease. J Psychiatr Res 1997; 31: 657-660.
14. Zuliani G, Ranzini M, Guerra G, Rossi L, Munari MR, Zurlo A, Volpato S, Atti AR, Ble A, Fellin R: Plasma cytokines profile in older subjects with late onset al.zheimer's disease or vascular dementia. J Psychiatr Res 2007; 41: 686-693.
15. Zuliani G, Cavalieri M, Galvani M, et al.: Markers of endothelial dysfunction in older subjects with late onset al.zheimer's disease or vascular de mentia. J Neurological Sci 2008; 272: 164-170.
16. Paganelli R, Di Iorio A, Patricelli L, Ripani F, Sparvieri E, Faricelli R, Iarlori C, Porreca E, Di Gioacchino M, Abate G: Proinflamatory cytokines in sera of elderly patients with dementia: levels in vascular injury are higher than those of mild-moderate Alzheimer's disease patients. Exp Gerontol 2002; 37: 257-263.
17. Ravaglia G, Forti P, Maioli F, Chiappelli M, Montesi F, Tumini E, Mariani E, Licastro F, Patterson C: Blood inflammatory markers and risk of dementia: The Conselice Study of Brain Aging. Neurobiol Aging 2007; 28: 1810-1820. (Pubitemid 47539699)
18. Dik MG, Jonker C, Hack CE, Smit JH, Comijs HC, Eikelenboom P: Serum inflammatory proteins and cognitive decline in older persons. Neurology 2005; 64: 1371-1377.
19. Jordanova V, Stewart R, Davies E, Sherwood R, Prince M: Markers of inflammation and cognitive decline in an African-Caribbean population. Int J Geriatr Psychiatry 2007; 22: 966-973.
20. Schram MT, Euser SM, de Craen AJM, Witteman JC, Frolich M, Hofman A, Jolles J, Breteler MMB, Westendorp RGJ: Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc 2007; 55: 708-716.
21. Teunissen CE, van Boxtel MPJ, Bosma, H, Bosmans E, Delanghe J, De Bruijn C, Wauters A, Maes M, Jolles J, Steinbusch HWM, de Vente J: Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunology 2003; 134: 142-150.
22. Weaver JD, Huang MH, Albert M, Harris T, Rowe JW, Seeman TE: Interleukin-6 and risk of cognitive decline: MacArthur Studies of Successful Aging. Neurology 2002; 59: 371-378.
23. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tylavsky FA, Newman AB: The metabolic syndrome, inflammation and risk of cognitive decline. J Am Med Assoc 2004; 292: 2237-2242.
24. Bruunsgaard H, Andersen-Ranberg K, Jeune B, Pedersen AN, Skinhoj P, Pedersen BK: A high plasma concentration of TNF-α is associated with dementia in centenarians. J Gerontol 1999; 54A:357-364.
25. Baune BT, Ponath G, Golledge J, Varga G, Arolt V, Rothermundt M, Berger K: Association between IL-8 cytokine and cognitive performance in an elderly general population - the MEMO-Study. Neurobiol Aging 2008; 29: 937-944.
26. Elwan O, Madkour O, Elwan F, Mostafa M, Helmy AA, Abdel-Naseer M, Shafy SA, Faiuomy NE: Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study. J Neurologic Sci 2003; 211: 15-22.
27. Komulainen P, Lakka TA, Kivipelto M, et al.: Serum high sensitivity C-reactive protein and cognitive function in elderly women. Age Aging 2007; 36: 443-448.
28. Ravaglia G, Forti P, Mailoi F, et al.: Serum Creactive protein and cognitive function in healthy elderly Italian community dwellers. J Gerontol Med Sci 2005; 60A:1017-1021.
29. Bagnoli S, Celline E, Tede A, Nacmias B, Piacentini S, Bessi V, Bracco L, Sorbi S: Association of IL-10 promoter polymorphism in Italian Alzeimer's disease. Neurosci Lett 2007; 418: 262-265.
30. Motta M, Imbesi R, Di Rosa M, Stivala F, Malaguarnera L: Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression. Immunol Lett 2007; 114: 46-51.
31. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson A, Oden A, Svanborg A: Fifteen-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-1145. (Pubitemid 126512042)
32. Roberts RO, Geda YE, Knopman DS, Boeve BE, Christianson TJH, Pankratz VS, Kullo IJ, Tangalos EG: Association of C-reactive protein with mild cognitive impairment. Alzheimers Dement 2009; 5: 398-405.
33. Haan MA, Aiello AE, West NA, Jagust WJ: C-reactive protein and rate of dementia in carriers and non carriers of Apolipoprotein APOE4 genotype. Neurobiol Aging 2008; 29: 1774-1782.
34. Forlenza OV, Breno SD, Talib LL, Mendoza VA, Ojopi E, Gattaz WF, Teixeira AL: Increased serum IL-1-level in Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Dis 2009; 28: 507-512.
35. Sachdev P, Brodaty H, Reppermund S, Kochan NA, Trollor JN, Draper B, Slavin M, Crawford J, Kang K, Broe A, Mather K, Lux O, Memory and Ageing Study Team: The Sydney Memory and Ageing Study (MAS): methodology and baseline medical and neuropsychiatric characteristics of an elderly epidemiological non-demented cohort of Australians aged 70-90 years. Int Psychogeriatr 2010; 19: 1-17.
36. Danesh J, et al.: Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199-204.
37. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F: Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systemic review and meta-analysis. Lancet Neurol 2005; 4: 371-380.
38. Strachan MWJ, Reynolds RM, Frier BM, Mitchell RJ, Price JF: The relationship between type 2 diabetes and dementia. Br Med Bull 2008; 88: 131-146.
39. Wärnberg J, Gomez-Martinez S, Romeo J, Diaz LE, Marcos A: Nutrition, inflammation and cognitive function. Ann NY Acad Sci 2009; 1153: 164-175.
40. Lezak MD, Howieson DB, Loring DW: Neuropsychological Assessment, ed 4. New York, Oxford University Press, 2004.
41. Wilson CJ, Finch CE, Cohen HJ: Cytokines and cognition: the case for a head-to-toe paradigm. J Am Geriatr Soc 2002; 50: 2041-2056.
42. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey MB, Leirer VO: Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1983; 17: 37-49.
43. Sheikh JI, Yesavage JA, Brooks JO, III, Friedman LF, Gratzinger P, Hill RD, Zadeik A, Crook T: Proposed factor structure of the Geriatric Depression Scale. Int Psychogeriatr 1991; 3: 23-28.
44. Corder EH, Saunders AM, Strittmatter WJ, et al.: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923.
45. Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545-548.
46. SPSS Statistics, Rel. 17.0.0. Chicago, SPSS Inc., 2008.
47. Blom G: Statistical Estimates and Transformed Beta-Variables. New York, John Wiley and Sons, 1958.
48. Zahorska-Markiewicz B, Janowska J, Olszanecka- Glinianowicz M, Zurakowski A: Serum concentrations of TNF-alpha and soluble TNF-alpha receptors in obesity. Int J Obes Relat Metab Disord 2000; 24: 1392-1395.
49. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
50. Kern PA, et al.: The expression of tumor necrosis factor in adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111-2119.
51. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415.
52. Berberoglu M: Evaluation of the correlation between serum tumor necrosis factor-alpha and relative body mass index (RBMI) in childhood. J Pediatr Endocrinol Metab 2001; 14: 543-547.
53. Li Y, Dai Q, Jackson JC, Zhang J: Overweight is associated with decreased cognitive function among school-age children and adolescents. Obesity 2008; 16: 1809-1815.
54. Gunstad J, Paul RH, Cohen RA, Tate DF, Spitznagel MB, Gordon E: Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Compr Psychiatry 2007; 48: 57-61.
55. Gustafson D: Life course of adiposity and dementia. Eur J Pharmacol 2008; 585: 163-175.
56. Naderali EK, Ratcliffe SH, Dale M: Obesity and Alzheimer's disease: a link between body weight and cognitive function in the old age. Am J Alzheimers Dis Other Demen 2009; 24: 445-449.
57. Cournot M, Marquie JC, Ansiau D, Martinaud C, Fonds H, Ferrieres J, Ruidavets JB: Relation between body mass index and cognitive function in healthy middle aged men and women. Neurology 2006; 67: 1208-1214.
58. Fergenbaum JH, Burce S, Lou W, Hanley AJG, Greenwood C, Young TK: Obesity and lowered cognitive performance in a Canadian First Nations population. Obesity 2009; 17: 1957-1963.
59. Gallagher D, Visser M, Sepulveda D, Pearson RN, Harris T, Heymsfield SB: How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol 1996; 143: 228-239.
60. Busse A, Hensel A, Gühne U, Angermeyer MC, Riedel-Heller SG: Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 2006; 67: 2176-2185.
61. Jordanova V, Stewart R, Davies E, Sherwood R, Prince M: Markers of inflammation and cognitive decline in an African-Caribbean population. Int J Geriatr Psychiatry 2007; 22: 966-973.
62. Sasazuki S, Inoue M, Sawada N, Iwasaki M, Shimazu T, Yamaji T, Tsugane S, the Japan Public Health Center-Based Prospective Study Group: Plasma levels of C-reactive protein and serum amyloid A and gastric cancer in a nested case-control study: Japan Public Health Center-based prospective study. Carcinogenesis 2010; 31: 712-718.
63. Goldberger G, Bing DH, Sipe JD, Rits M, Colten HR: Transcriptional regulation of genes enconding the acute phase protein CRP, SAA and C3. J Immunol 1987; 138: 3967-3971.
64. Ridker PM, Haughie P: Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. J Investig Med 1998; 46: 391-395.
65. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97: 425-428.
66. Ruitenberg A, Ott A, van Swieten JC, Hofman A, Breteler MM: Incidence of dementia: does gender make a difference? Neurobiol Aging 2001; 22: 575-578.
67. Soeda S, Koyanagi S, Kuramoto Y, Kimura M, Oda M, Kozako T, Hayashida S, Shimeno H: Anti-apoptotic roles of the plasminogen activator inhibitor-1 as a neurotropic factor in the central nervous system. Thromb Hemost 2008; 100: 1014-1020.
68. Flavin MP, Zhao G: Tissue plasminogen activator protects hippocampal neurons from oxygen-glucose deprivation injury. J Neurosci Res 2001; 63: 388-394.
69. Akiyama H, et al.: Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383-421.
70. Borroni B, Premi E, Di Luca M, Padovani A: Combined biomarkers for early Alzheimer disease diagnosis. Curr Med Chem 2007; 14: 1171-1178.
71. Teunissen CE, de Vente J, Steinbusch HWM, de Bruijn C: Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging 2002; 23: 485-508.
72. Ray S, Britschgi M, Herbet C, Takeda- Uchimura Y, Boxer A, et al.: Classification and prediction of clinical Alzheimer's diagnosis based on plasma signalling proteins. Nat Med 2007; 13: 1359-1362.
73. Wyss-Coray T: Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006; 12: 1005-1015.
74. Visser PJ, Brodaty H: For debate: MCI is not a clinically useful concept. Int Psychogeriatr 2006; 18: 402-409.
75. Winblad B, Palmer K, Kivipelto M, et al.: Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256: 240-246.
76. Kochan N, Slavin M, Brodaty H, Crawford J, Trollor J, Draper B, Sachdev P: Impact of different impairment criteria on prevalence of 'objective' mild cognitive impairment in a community sample. Am J Geriatr Psychiatry, in press.